Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
Age
disease-modifying treatments
infection risk
multiple sclerosis
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
30
11
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
Disease-modifying treatments (DMTs) can increase the risk of infections in multiple sclerosis (MS). Aged individuals are usually excluded from clinical trials, and there is uncertainty regarding safety of immunosuppressive DMTs in these patients. To investigate the association of DMTs, ageing and other clinical variables with risk of infections in MS patients. Prospective single-centre observational study collecting information on occurrence, type and grade of infections in patients followed at the MS centre, Lugano (Switzerland). Associations with infection risk were tested using multivariable Poisson and Cox regressions. A total of 503 patients were included (injectables/untreated, Treatment with MAB and oral DMTs is associated with higher incidence of infections, with a stronger effect in young MS patients. Disability appears the main predictor of severe infections regardless of treatment.
Sections du résumé
BACKGROUND
UNASSIGNED
Disease-modifying treatments (DMTs) can increase the risk of infections in multiple sclerosis (MS). Aged individuals are usually excluded from clinical trials, and there is uncertainty regarding safety of immunosuppressive DMTs in these patients.
OBJECTIVE
UNASSIGNED
To investigate the association of DMTs, ageing and other clinical variables with risk of infections in MS patients.
METHODS
UNASSIGNED
Prospective single-centre observational study collecting information on occurrence, type and grade of infections in patients followed at the MS centre, Lugano (Switzerland). Associations with infection risk were tested using multivariable Poisson and Cox regressions.
RESULTS
UNASSIGNED
A total of 503 patients were included (injectables/untreated,
CONCLUSION
UNASSIGNED
Treatment with MAB and oral DMTs is associated with higher incidence of infections, with a stronger effect in young MS patients. Disability appears the main predictor of severe infections regardless of treatment.
Identifiants
pubmed: 37786964
doi: 10.1177/13524585231199820
doi:
Substances chimiques
Immunosuppressive Agents
0
Antibodies, Monoclonal
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1765-1775Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The employer (Department of Neurology, Regional Hospital Lugano (EOC), Lugano, Switzerland) receives financial support from Teva, Merck Serono, Biogen Idec, Bayer Schering, Genzyme, Roche and Novartis. The submitted work is not related to these agreements.